New hope for breast cancer patients who run out of options
NCT ID NCT07340619
Summary
This study is testing whether adding a new drug called prifetrastat to the standard hormone therapy fulvestrant can help control advanced breast cancer that has stopped responding to current treatments. It will enroll 51 adults with hormone-sensitive, HER2-negative breast cancer that has spread and progressed despite prior therapy. The main goal is to see if the combination reduces cancer-related genetic markers in the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC (STAGE IV) MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.